AHP Settlement

Diet Drug Class Action Settlement

Phen Phen / Fenphen / Fen-Phen Settlement with American Home Products Corporation

National Diet Drug Settlement Claims Website
All official court notices, claims forms, and other information concerning the national settlement (MDL 1203) are now available on line, as well as online registration to obtain a copy of the official notice package.  If you are or believe that you are a class member, you should visit the official site. Visit  MDL1203 National Class Action settlement Website

The following is a brief summary of the Class Action Settlement.

Settlement Matrix Compensation Benefits Guide for Physicians, Attorneys and Class Members:

A. A nationwide Class Action Settlement has been reached with American Home Products Corporation which will resolve the claims of individuals who took the diet drugs Pondimin and/or Redux.

B. Under the Settlement, patients who took the diet drugs Pondimin and/or Redux have a right to receive compensation if they have developed serious levels of valvular heart disease.

C. The amounts which individuals are entitled to recover under this Settlement depend on the person's age at diagnosis of valvular heart disease, the person's "Level of Severity" and additional criteria as set forth below. Payments will be made according to these "Matrices":

Matrix A-1 For Diet Drug Recipients

 
 Level < 24 25-29 30-34 35-39
I $123,750 $117,563 $111,685 $106,100
II $643,500 $611,325 $580,759 $551,721
III $940,500 $893,475 $848,801 $806,361
IV $1,336,500 $1,269,675 $1,206,191 $1,145,881
V $1,485,000 $1,410,750 $1,340,213 $1,273,202
Level 40-44 45-49 50-54 55-59
I $100,795 $95,755 $90,967 $86,419
II $524,135 $497,928 $473,032 $449,381
III $766,043 $727,741 $691,354 $656,786
IV $1,088,587 $1,034,158 $982,450 $933,327
V $1,209,542 $1,149,065 $1,091,612 $1,037,031
Level 60-64 65-69 70-79
I $82,098 $73,888 $36,944
II $426,912 $384,221 $192,111
III $623,947 $561,552 $280,776
IV $886,661 $797,995 $398,998
V $985,180 $886,662 $443,331

Matrix A-2 For Derivative Claimants

Level < 24 25-29 30-34 35-39
I $1,250 $1,187 $1,128 $1,072
II $6,500 $6,175 $5,866 $5,573
III $9,500 $9,025 $8,574 $8,145
IV $13,500 $12,825 $12,184 $11,575
V $15,000 $14,250 $13,537 $12,861
Level 40-44 45-49 50-54 55-59
I $1,018 $967 $919 $873
II $5,294 $5,030 $4,778 $4,539
III $7,738 $7,351 $6,983 $6,634
IV $10,996 $10,446 $9,924 $9,428
V $12,218 $11,607 $11,026 $10,475
Level 60-64 65-69 70-79
I $829 $739 $500
II $4,312 $3,842 $1,921
III $6,302 $5,616 $2,808
IV $8,956 $7,980 $3,990
V $9,951 $8,867 $4,433

I

Matrix B-1 For Diet Drug Recipients

 
Level < 24 25-29 30-34 35-39
I $24,750 $23,513 $22,337 $21,221
II $128,700 $122,265 $116,152 $110,344
III $188,100 $178,695 $169,760 $161,272
IV $267,300 $253,935 $241,238 $229,176
V $297,000 $282,150 $268,043 $254,641
Level 40-44 45-49 50-54 55-59
I $20,159 $19,152 $18,194 $17,284
II $104,827 $99,586 $94,606 $89,876
III $153,208 $145,548 $138,270 $131,357
IV $217,717 $206,831 $196,489 $186,665
V $241,908 $229,813 $218,322 $207,406
Level 60-64 65-69 70-79
I $16,420 $14,778 $7,389
II $85,383 $76,844 $38,422
III $124,790 $112,310 $56,155
IV $177,332 $159,599 $79,800
V $197,036 $177,332 $88,666

 

Matrix B-2 For Derivative Claimants

Level < 24 25-29 30-34 35-39
I $500 $500 $500 $500
II $1,300 $1,235 $1,173 $1,115
III $1,900 $1,805 $1,715 $1,629
IV $2,700 $2,565 $2,437 $2,315
V $3,000 $2,850 $2,707 $2,572
Level 40-44 45-49 50-54 55-59
I $500 $500 $500 $500
II $1,059 $1,006 $956 $908
III $1,548 $1,470 $1,397 $1,327
IV $2,199 $2,089 $1,985 $1,885
V 2,444 $2,321 $2,205 $2,095
Level 60-64 65-69 70-79
I $500 $500 $500
II $862 $768 $500
III $1,260 $1,123 $562
IV $1,791 $1,596 $798
V $1,990 $1,773 $886
 

 

For the Diet Drug Recipient: The circumstances which determine whether "Matrix A-1" or "Matrix B-1" is applicable are as follows:

1. Matrix A-1: Diet Drug Recipients who ingested Pondimin® and/or Redux™ for 61 or more days, who were diagnosed as FDA Positive, whose conditions are eligible for matrix payments but who do not have any condition or circumstance which makes Matrix B-1 applicable, receive payments on Matrix A-1.

2. Matrix B-1: Diet Drug Recipients who are eligible for matrix payments and to whom one or more of the following conditions apply, receive payments on Matrix B-1:

bulletFor claims as to the mitral valve, Diet Drug Recipients who were diagnosed as having Mild Mitral Regurgitation (regardless of the duration of ingestion of Pondimin® and/or Redux™).
bulletDiet Drug Recipients who ingested Pondimin® and/or Redux™ for 60 days or less, who were diagnosed as FDA Positive.
bulletDiet Drug Recipients who ingested Pondimin® and/or Redux™ for 61 or more days, who were diagnosed as FDA Positive with any of the following conditions:

With respect to an aortic valve claim:

bulletThe following congenital aortic valve abnormalities: unicuspid, bicuspid or quadricuspid valves, ventricular septal defect associated with aortic regurgitation;
bulletAortic dissection involving the aortic root and/or aortic valve;
bulletAortic sclerosis in people who are > 60 years old as of the time they are first diagnosed as FDA Positive; Aortic root dilatation >5.0 cm;
bulletAortic stenosis with an aortic valve area <1.0 square centimeter by the Continuity Equation.

With respect to a mitral valve claim:

bulletThe following congenital mitral valve abnormalities: parachute valve, cleft of the mitral valve associated with atrial septal defect;
bulletMitral Valve Prolapse as determined by Echocardiogram. "Mitral Valve Prolapse" refers to a condition where (a) the echoardiogram video tape or disk includes the parasternal long axis view and (b) that echocardiographic view shows displacement of one or both mitral leaflets >2mm above the atrial-ventricular border during systole, and >5mm leaflet thickening during diastole, as determined by a Board-Certified Cardiologist.
bulletChordae tendineae rupture or papillary muscle rupture; or acute myocardial infarction associated with acute mitral regurgitation;
bulletMitral annular calcification;
bulletM-Mode and 2-D Echocardiographic evidence of rheumatic mitral valves (doming of the anterior leaflet and/or anterior motion of the posterior leaflet and/or commissural fusion), except where there is no evidence of rheumatic valve disease upon pathological examination of mitral valve tissue.

With respect to claims for the aortic and/or
mitral valve(s):

bulletHeart valve surgery prior to Pondimin® and/or Redux™ use on the valve that is the basis of claim;
bulletBacterial endocarditis prior to Pondimin® and/or Redux™ use;
bulletFDA Positive regurgitation (confirmed by Echocardiogram) prior to Pondimin® and/or Redux™ use for the valve that is the basis of claim;
bulletSystemic Lupus Erythernatosus or Rheumatoid Arthritis1 and valvular regurgitation and/or valvular abnormalities of a type associated with those conditions2 ;
bulletCarcinoid tumor of a type associated with aortic and/or mitral valve lesions;
bulletHistory of daily use of methysergide or ergotamines for a continuous period of longer than 120 days.

For the Diet Drug Recipients' spouses, children and "significant others":

Diet Drug Recipients' spouses, children and "significant others" ("Derivative Claimants") may also be eligible for Matrix Payments under the law and if so, they will be paid an amount set forth in one of the "Derivative Matrices".

1.) Matrix A-2 will be used where the Diet Drug Recipient was eligible for Matrix A-1 payments.

2.) Matrix B-2 will be used where the Diet Drug Recipient was eligible for Matrix B-1 payments.

Under the matrices, the "Levels of Severity" which qualify Diet Drug Recipients for recovery on the Settlement matrices are as follows:

Levels of Severity

Matrix Level I:

Matrix Level I is severe left sided valvular heart disease without complicating factors, and is defined as one of the following:

(a)Severe aortic regurgitation (AR) > 5O% jet height/left ventricular outflow tract height (JH/LVOTH)3 and/or severe mitral regurgitation (MR) > 40% regurgitant jet area/left atrial area (RJA/LAA)4,5; and no complicating factors as defined below;

(b) FDA Positive valvular regurgitation6 with bacterial endocarditis contracted after commencement Pondimin and/or Redux use.

Matrix Level II:

Matrix Level II is left sided valvular heart disease with complicating factors, and is defined as:

(a) Moderate AR (25% - 49% JH/LVOTH)7 or Severe AR (> 50% JH/LVOTH)8 with one or more of the following:

i) Pulmonary hypertension secondary to severe aortic regurgitation with a peak systolic pulmonary artery pressure > 40 mm Hg measured by cardiac catheterization or with a peak systolic pulmonary artery pressure > 45 mm Hg9 measured by Doppler Echocardiography, at rest, utilizing standard procedures10,11 assuming a right atrial pressure of 10 mm Hg;

ii) Abnormal left ventricular end-systolic dimension > 50 mm12 by M-mode or 2-D Echocardiography or abnormal left ventricular end-diastolic dimension > 70 mm13 as measured by M-mode or 2-D Echocardiography;

iii ) Ejection fraction of > 5O%14; and/or

(b) Moderate MR (20% - 40% RJA/LAA)15 or Severe MR (> 40% RJA/LAA)16 with one or more of the following:

i) Pulmonary hypertension secondary to valvular heart disease with peak systolic pulmonary artery pressure > 40 mm Hg measured by cardiac catheterization or with a peak systolic pulmonary artery pressure > 45 mm Hg17 measured by Doppler Echocardiography, at rest, utilizing the procedures described in Section F.2.(a)(i);

ii) Abnormal left atrial supero-inferior systolic dimension > 5.3 cm18 (apical four chamber view) or abnormal left atrial antero-posterior systolic dimension > 4.0 cm (parasternal long axis view) measured by 2-D directed M-mode or 2-D echocardiography with normal sinus rhythm using sites of measurement recommended by the American Society of Echocardiography19;

iii) Abnormal left ventricular end-systolic dimension > 45 mm20 by M-mode or 2-D Echocardiogram;

iv) Ejection fraction of <60%21.

v) Arrhythmias, defined as chronic atrial fibrillation/flutter that cannot be converted to normal sinus rhythm, or atrial fibrillation/flutter requiring ongoing medical therapy, either of which are associated with left atrial enlargement; as defined in Section F.2.(b)(ii).

Matrix Level III

Matrix Level III is left sided valvular heart disease requiring surgery or conditions of equal severity, and is defined as:

(a) Surgery to repair or replace the aortic and/or mitral valve (s) following the use of Pondimin® and/or ReduxTM or

(b) Severe regurgitation and the presence of ACC/AHA Class I indications for surgery to repair or replace the aortic22 and/or mitra123 valve(s) and a statement from the attending Board Certified Cardiothoracic Surgeon or Board Certified Cardiologist supported by medical records regarding the recommendations made to the patient concerning valvular surgery, with the reason why the surgery is not being performed; or

(c) Qualification for payment at Matrix Level l(b) (as described in Section F.1.b. above) or Matrix Level II and, in addition, a stroke due to bacterial endocarditis contracted after use of Pondimin® and/or ReduxTM or as a consequence of chronic atrial fibrillation with left atrial enlargement as defined in Section F.2.(b)(ii) which results in a permanent condition which meets the criteria of AHA Stroke Outcome Classification24 Functional Level II, determined six months after the event.

Matrix Level IV:

Matrix Level IV is defined as follows:

(a) Qualification for payment at Matrix Level l (b) (as described in Section F.1.b. above), II or III and, in addition, a stroke due to bacterial endocarditis contracted after use of Pondimin® and/or ReduxTM- or as a consequence of chronic atrial fibrillation with left atrial enlargement as defined in Section F.2.(b)(ii) which results in a permanent condition which meets the criteria of AHA Stroke Outcome Classification25 Functional Level III, determined six months after the event; or

(b) Qualification for payment at Matrix Level l(b), II, or III and, in addition, a peripheral embolus due to Bacterial Endocarditis contracted after use of Pondimin® and/or ReduxTM or as a consequence of atrial fibrillation with left atrial enlargement as defined in Section F.2.(b)(ii) which results in severe permanent impairment to the kidneys, abdominal organs, or extremities, where severe permanent impairment means:

i) for the kidneys, chronic severe renal failure requiring hemodialysis or Continuous Abdominal Peritoneal Dialysis for more than six months;

ii) for the abdominal organs, impairment requiring intra-abdominal surgery; iii) for the extremities, impairment requiring amputation of a major limb; or

(c) The individual has the following:

i) Qualification for payment at Matrix Level III; and

ii) New York Heart Association Functional Class I or Class II symptoms as documented by the attending Board Certified Cardiothoracic Surgeon or Board Certified Cardiologist; and

iii) Valvular repair and replacement surgery or ineligibility for surgery due to medical reasons as documented by the attending Board Certified Cardiothoracic Surgeon or BoardCertified Cardiologist; and

iv) Significant damage to the heart muscle, defined as: (a) a left ventricular ejection fraction <30% with aortic regurgitation or a left ventricular ejection fraction <35% with mitral regurgitation in patients who have not had surgery and meet the criteria of Section F.3.(b) or (b) a left ventricular ejection fraction<40% six months after valvular repair or replacement surgery in patients who have had such surgery; or

(d) The individual has had valvular repair or replacement surgery and has one or more of the following complications which occur either during surgery, within 30 days after surgery, or during the same hospital stay as the surgery:

i) Renal failure, defined as chronic, severe renal failure requiring regular hemodialysis or Continuous Abdominal Peritoneal Dialysis for greater than six months following aortic and/or mitral valve replacement surgery;

ii) Peripheral embolus following surgery resulting in severe permanent impairment to the kidneys, abdominal organs, or extremities;

iii) Quadriplegia or paraplegia resulting from cervical spine injury during valvular heart surgery; or

(e)A stroke caused by aortic and/or mitral valve surgery and the stroke has produced a permanent condition which meets the criteria of the AHA Stroke Outcome Functional Levels II or III determined six months after the event.26

(f)The individual has had valvular repair or replacement surgery and suffers from post operative endocarditis, mediastinitis or sternal osteomyelitis, either of which requires reopening the median sternotomy for treatment, or a post-operative serious infection defined as HIV or Hepatitis C within six months of surgery as a result of blood transfusion associated with the heart valve surgery.

(g) The individual has had valvular repair or replacement surgery and requires a second surgery through the sternum within 18 months of the initial surgery due to prosthetic valve malfunction, poor fit, or complications reasonably related to the initial surgery.

 

Matrix Level V:

Matrix Level V is defined as:

(a) Endocardial Fibrosis (A) diagnosed by (1) endomyocardial biopsy that demonstrates fibrosis and cardiac catheterization that demonstrates restrictive cardiomyopathy or (2) autopsy that demonstrates endocardial fibrosis and (B) other causes, including dilated cardiomyopathy, myocardial infarction, amyloid, Loeffler's endocarditis, endomyocardial fibrosis as defined in Braunwald (involving one or both ventricles, located in the inflow tracts of the ventricles, commonly involving the chordae tendineae, with partial obliteration of either ventricle commonly present)27 focal fibrosis secondary to valvular regurgitation (e.g., "jet lesions"), focal fibrosis secondary to catheter instrumentation, and hypertrophic cardiomyopathy with septal fibrosis, have been excluded; or

(b) Left sided valvular heart disease with severe complications, defined as Matrix Levels I(b) (as described in Section F.1.b. above), III or IV above with one or more of the following:

i) A severe stroke following aortic and/or mitral valve surgery or due to bacterial endocarditis contracted after use of Pondimin® and/or ReduxTM or as a consequence of chronic atrial fibrillation with left atrial enlargement as defined in Section F.2.b.(ii) and the severe stroke has resulted in a permanent condition which meets the criteria of AHA Stroke Outcome Classification28 Functional Levels IV or V, determined six months after the event; or

ii) The individual has the following:

 

 

a) Qualification for payment at Matrix Levels III or IV; and

b) New York Heart Association Functional Class III or Class IV symptoms as documented by the attending Board-Certified Cardiothoracic Surgeon or Board-Certified Cardiologist; and

c)Valvular repair or replacement surgery or ineligibility for surgery due to medical reasons as documented by the attending Board-Certified Cardiothoracic Surgeon or Board-Certified Cardiologist; and

d)Significant damage to the heart muscle, defined as:

(i) a left ventricular ejection fraction <30% with aortic regurgitation or a left ventricular ejection fraction <35% with mitral regurgitation, in patients who have not had surgery and meet the criteria of Section F.3.b.or

(ii) a left ventricular ejection fraction <40% six months after valvular repair or replacement surgery in patients who have had such surgery; or

iii) Heart transplant;

iv) Irreversible pulmonary hypertension (PH) secondary to valvular heart disease defined as peak?systolic pulmonary artery pressure >50 mm Hg29 (by cardiac catheterization) at rest following repair or replacement surgery of the aortic and/or mitral valve(s);

v) Persistent non-cognitive state30 caused by a complication of valvular heart disease (e.g., cardiac arrest) or valvular repair/replacement surgery supported by a statement from the attending Board Certified Cardiothoracic Surgeon or Board Certified Cardiologist, supported by medical records; or

(c) Death resulting from a condition caused by valvular heart disease or valvular repair/replacement surgery which occurred post Pondimin® and/or ReduxTMuse supported by a statement from the attending Board Certified Cardiothoracic Surgeon or Board Certified Cardiologist, supported by medical records; or

(d) The individual otherwise qualifies for payment at Matrix Level II, III, or IV and suffers from ventricular fibrillation or sustained ventricular tachycardia which results in hemodynamic compromise.

If you need assistance in making your claim, including getting expert doctors to prepare the necessary medical documentation required by the Class Action Settlement, please Contact Us. 

 

Home

Hit Counter

Dallas Office
13250 Branch View Lane
Dallas, TX  75234 

1-888-405-LAWS (5297) * 972-243-LAWS (5297)

Email:  Contact Us!